| Status | In progress |
| Process | STA 2018 |
| ID number | 1189 |
Provisional Schedule
| Expected publication | 23 February 2020 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TACommC@nice.org.uk
| Evidence Review Group / Assessment Group | Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors | Shionogi (naldemedine) |
| Others | Department of Health |
| NHS England | |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association |
Commentators
| Comparator companies | Kyowa Kirin (naloxegol) |
| Norgine Pharmaceuticals (sterculia/ frangula, macrogol, docusate sodium enema) | |
| Novartis (senna) – (CAU not signed, not participating) | |
| Orbis Consumer Products (glycerol suppositories) – (CAU not signed, not participating) | |
| Pinewood Healthcare (sodium citrate enema) – (CAU not signed, not participating) | |
| Reckitt Benckiser Healthcare (senna) – (CAU not signed, not participating) | |
| Sandoz (lactulose) – (CAU not signed, not participating) | |
| Sanofi (bisacodyl, docusate, macrogol sodium picosulfate) – (CAU not signed, not participating) | |
| Stirling Anglian (macrogol) – (CAU not signed, not participating) | |
| Swedish Orphan Biovitrum (methylnaltrexone bromide) – (CAU not signed, not participating) | |
| Teva UK (lactulose) – (CAU not signed, not participating) | |
| Thornton & Ross (macrogol, magnesium hydroxide, glycerol suppositories, senna) – (CAU not signed, not participating) | |
| UCB Pharma (sodium citrate enema, docusate) – (CAU not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 April 2019 | Invitation to participate |
| 05 April 2019 | In progress, To appraise the clinical and cost effectiveness of Suggested remit - To appraise the clinical and cost effectiveness of gilteritinib within its marketing authorisation for treating relapsed or refractory positive acute leukaemia. |
| 23 February 2018 | The Department of Health has asked the Institute to conduct an appraisal of naldemedine for treating opioid-induced constipation which was due to start in mid-January 2018. We have been informed by the company of a delay to the licensing application, therefore, NICE will suspend and reschedule this appraisal in line with the new timings. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance